Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Pharmalot
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

Sanofi makes a steep bid for a hemophilia business, but did it make a good case?

  • Ed Silverman

By Ed Silverman Jan. 22, 2018

Reprints
Sanofi
Jacques Brinon/AP

Buffeted by problems with its all-important diabetes franchise, Sanofi (SNY) is bidding $11.6 billion for Bioverativ (BIVV) — a hemophilia company spun off by Biogen (BIIB) — hoping it will help solve its strategic and financial woes.

But skepticism abounds.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

International team creates first chimeric human-monkey embryos
International team creates first chimeric human-monkey embryos
‘Essentially witchcraft’: A former naturopath takes on her colleagues
‘Essentially witchcraft’: A former naturopath takes on her colleagues
Study suggests diabetes screening should be guided by age,…
Study suggests diabetes screening should be guided by age, not weight
J&J loses a patent battle in India over a…
J&J loses a patent battle in India over a crucial tuberculosis drug
Pharmalittle: FDA panel backs conditional approval for Biogen ALS…
Pharmalittle: FDA panel backs conditional approval for Biogen ALS drug; pharma fights tactic for lowering specialty…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’ ‘massive payouts’ to execs

Recommended Stories